Additionally, the company, which makes T-cell drugs for cancer treatment, is launching a search for a new CEO. Its current CEO Nick Leschly will become chair of the company’s board. The company said the cuts will generate $130 million in savings.
For the job cuts, the company is taking a one-time charge of $9 million. 2seventy no longer expects to generate $470 million to $570 million in 2023 revenue.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
